These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3491565)

  • 1. A possible new therapy of systemic lupus erythematosus (SLE).
    Borel H; Bastian D; Cooper B; Borel Y
    Ann N Y Acad Sci; 1986; 475():296-306. PubMed ID: 3491565
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
    Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
    Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New prospects for the treatment of systemic lupus erythematosus].
    Iniestra Flores F; Orea Solano M
    Rev Alerg Mex; 2002; 49(6):176-80. PubMed ID: 12561649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic lupus erythematosus.
    Goust JM; Tsokos G
    Immunol Ser; 1993; 58():437-49. PubMed ID: 8424987
    [No Abstract]   [Full Text] [Related]  

  • 5. Soluble MHC class II-driven therapy for a systemic lupus erythematosus murine experimental in vitro and in vivo model.
    Bakela K; Dimakopoulou M; Batsou P; Manidakis N; Athanassakis I
    Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29412476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.
    Fan JL; Himeno K; Tsuru S; Nomoto K
    Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The mechanisms of antinuclear antibody production and its pathogenicity in systemic autoimmune diseases].
    Fujii T
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Apr; 29(2):57-64. PubMed ID: 16651703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE.
    Shoenfeld Y; Blank M; Aharoni R; Teitelbaum D; Arnon R
    Immunol Lett; 1993 May; 36(2):109-16. PubMed ID: 8349307
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of autoimmunity in experimental lupus erythematosus by soluble immune response suppressor.
    Krakauer RS; Strober W; Rippeon DL; Waldmann TA
    Science; 1977 Apr; 196(4285):56-9. PubMed ID: 300174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals.
    Datta SK; Kaliyaperumal A; Mohan C; Desai-Mehta A
    Lupus; 1997; 6(3):333-6. PubMed ID: 9296784
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmunity and lymphoid malignancy in New Zealand black mice.
    Talal N
    Prog Clin Immunol; 1974; 2():101-20. PubMed ID: 4141778
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic lupus erythematosus.
    Goust JM
    Immunol Ser; 1990; 50():449-63. PubMed ID: 2151125
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.
    Brosh N; Eilat E; Zinger H; Mozes E
    Immunology; 2000 Feb; 99(2):257-65. PubMed ID: 10692045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of murine lupus autoantibodies to DNA by administration of muramyl dipeptide and syngeneic anti-DNA IgG.
    Zouali M; Jolivet M; Leclerc C; Ravisse P; Audibert F; Eyquem A; Chedio L
    J Immunol; 1985 Aug; 135(2):1091-6. PubMed ID: 3874227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T and B cell recognition of idiotypes of anti-DNA autoantibodies.
    Gavalchin J; Staines NA
    Lupus; 1997; 6(3):337-43. PubMed ID: 9296785
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of sleep deprivation on the development of autoimmune disease in an experimental model of systemic lupus erythematosus.
    Palma BD; Gabriel A; Colugnati FA; Tufik S
    Am J Physiol Regul Integr Comp Physiol; 2006 Nov; 291(5):R1527-32. PubMed ID: 16809486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From nonspecific to specific immunosuppression: facts and speculation.
    Borel Y
    Springer Semin Immunopathol; 1984; 7(1):19-24. PubMed ID: 6204394
    [No Abstract]   [Full Text] [Related]  

  • 18. An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice.
    Wellmann U; Letz M; Schneider A; Amann K; Winkler TH
    Int Immunol; 2001 Dec; 13(12):1461-9. PubMed ID: 11717187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of NZB autoimmune phenotypes by the Sle1c murine lupus susceptibility interval.
    Giles BM; Tchepeleva SN; Kachinski JJ; Ruff K; Croker BP; Morel L; Boackle SA
    J Immunol; 2007 Apr; 178(7):4667-75. PubMed ID: 17372026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
    Wofsy D; Seaman WE
    J Immunol; 1987 May; 138(10):3247-53. PubMed ID: 3106478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.